Navigation Links
Study reveals potential immune benefits of vitamin D supplements in healthy individuals
Date:3/20/2013

(Boston) Research from Boston University School of Medicine (BUSM) shows that improving vitamin D status by increasing its level in the blood could have a number of non-skeletal health benefits. The study, published online in PLOS ONE, reveals for the first time that improvement in the vitamin D status of healthy adults significantly impacts genes involved with a number of biologic pathways associated with cancer, cardiovascular disease (CVD), infectious diseases and autoimmune diseases. While previous studies have shown that vitamin D deficiency is associated with an increased risk for the aforementioned diseases, these results go a step further and provide direct evidence that improvement in vitamin D status plays a large role in improving immunity and lowering the risk for many diseases.

Vitamin D is unique in that it can be both ingested and synthesized by the body with sun exposure. It is then converted by both the liver and kidneys to a form that the body can use. An individuals' level of vitamin D, or their vitamin D status, is determined by measuring the level of 25-hydroxyvitamin D in the blood. Vitamin D deficiency, which is defined as a status of less than 20 nanograms per milliliter (ng/mL) of 25-hydroxyvitamin D, can cause a number of health issues, including rickets and other musculoskeletal diseases. Recently, however, data suggests that vitamin D deficiency (<20 ng/mL) and vitamin D insufficiency (between 21-29 ng/mL) is linked to cancer, autoimmune diseases, infectious diseases, type 2 diabetes and cardiovascular disease.

The randomized, double-blind, single-site pilot trial involved eight healthy men and women with an average age of 27 who were vitamin D deficient or insufficient at the start of the trial. Three participants received 400 International Units (IUs) of vitamin D per day and five received 2,000 IUs per day for a two-month period. Samples of white blood cells (immune cells) were collected at the beginning of the two-month period and again at the end. A broad gene expression analysis was conducted on these samples and more than 22,500 genes were investigated to see if their activity increased or decreased as a result of the vitamin D intake.

At the end of the pilot, the group that received 2000 IUs achieved a vitamin D status of 34 ng/mL, which is considered sufficient, while the group that received 400 IUs achieved an insufficient status of 25 ng/mL.

The results of the gene expression analysis indicated statistically significant alterations in the activity of 291 genes. Further analysis showed that the biologic functions associated with the 291 genes are related to 160 biologic pathways linked to cancer, autoimmune diseases, infectious diseases and CVD.

Examining gene response elements, or sequences of DNA bases that interact with vitamin D receptors to regulate gene expression, they also identified new genes related to vitamin D status. To ensure that their observations were accurate, the researchers looked at 12 genes whose level of expression does not change, and those genes remained stable throughout the trial period.

"This study reveals the molecular fingerprints that help explain the non-skeletal health benefits of vitamin D," said Michael F. Holick, PhD, MD, professor of medicine, physiology and biophysics at BUSM and leading vitamin D expert who served as the study's corresponding author. "While a larger study is necessary to confirm our observations, the data demonstrates that improving vitamin D status can have a dramatic effect on gene expression in our immune cells and may help explain the role of vitamin D in reducing the risk for CVD, cancer and other diseases."


'/>"/>

Contact: Jenny Eriksen
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 2017 , ... Connance, a leading provider of healthcare predictive ... analytics drive reimbursement optimization, with a focus on denial management and claims statusing, ... traditional approach to denied and underpaid claims leaves money on the table and ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... assessments and consulting services, has published a new eBook titled “ 5 Questions ... Bridge, MSc, Associate Research Analyst on the Genetic Test Evaluation (GTE) team, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos ... and a host of new options for today’s modern senior. Brazos Towers at ... active, independent lifestyle they love while offering them the services to support that lifestyle ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. ... Cincinnati, OH for leading-edge care, whether or not they have a referral. Dr. ... BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without affecting the ...
(Date:6/20/2017)... ... June 20, 2017 , ... This ... program focused on finding product improvements that could reduce the occurrence of ... when they need help breathing or to provide medication. Sometimes, patient movement can ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... solutions, today announced that it will be presenting at the 7th ... AM PT. Erez Raphael , CEO, of DarioHealth will be ... will be held on June 6th & 7th, 2017 at the ... the small / micro-cap space. ...
Breaking Medicine Technology: